- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, FAHA, chief medical officer at Caladrius Biosciences.
We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, FAHA, chief medical officer at Caladrius Biosciences.
Transcript
As 1 of the scientists who found the CD34 cells 20 years ago, how has research and treatment evolved since its discovery?
In the past 20 years, we've had the opportunity to evaluate the ability of the CD34 cell to institute repair in patients who have suffered some sort of ischemic insult, whether it's a heart attack, heart failure, limb ischemia, or in the most recent case, coronary microvascular dysfunction, that's causing chest pain. The fascinating thing about this cell is that it has an unblemished track record, in terms of showing evidence for clinical benefit in every setting in which it's been tested. So, it's been quite interesting and quite encouraging, and we're now really approaching the point where these cells will be made available as part of the toolkit that doctors will have to treat patients with cardiovascular disease.
Can you describe the importance of treating CD34 cells in patients with CMD to lessen the risk of related adverse clinical outcomes?
Coronary microvascular dysfunction, or CMD, has only recently started to become recognized as a critical component, and perhaps the most important component that confers risk to patients with heart disease. We know that measurements of coronary microvascular dysfunction correlate with bad outcomes in patients. The worst your CMD, the higher the risk of cardiovascular events. What we do not yet know is whether improving coronary microvascular function results in a decrease in risk—kind of like blood pressure. Before we had blood pressure medicines, we knew that having high blood pressure was bad. We just didn't know if lowering blood pressure would reduce the risk of events–now we know that. Finally, we have a tool, as evidenced by this recent study, that appears to improve coronary microvascular function. So, now we'll be able to see what happens if we improve function–does that result in a decrease in bad events. So, we'll be able to answer that question.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
